Impurity in Some Compounded Tirzepatide ‘Potentially Dangerous,’ Eli Lilly Warns
(MedPage Today) — Compounded versions of tirzepatide (Mounjaro, Zepbound) containing vitamin B12 pose a potential safety risk to the public, Eli Lilly warned in an open letter on Thursday.
Following laboratory testing, the drugmaker said it uncovered…
Study Looks at Associations Between Semaglutide and Ischemic Optic Neuropathy
THURSDAY, March 12, 2026 — Formulation- and sex-specific associations are seen for semaglutide use with ischemic optic neuropathy, with increased odds in men and with Wegovy use, according to a study published online March 10 in the British Journal…
Lilly Flags ‘Concerning’ Impurities in Compounded Tirzepatide
Combining tirzepatide with vitamin B12, a common additive in compounded versions of the drug, yields an impurity that could alter the drug’s toxicity profile and pose safety risks to patients, the company said in an open letter.
Compounders prescribing GLP-1s put pricing pressure on Novo, Lilly
Hims won — for now.
Since 2022, telehealth companies and compounding pharmacies have brought a new type of competition for drugmakers. Pharma giants, long protected by patents and market exclusivity, suddenly found themselves undercut on price …
Lilly warns of impurity risk in certain compounded forms of Mounjaro and Zepbound
Compounded forms of the molecule behind Eli Lilly’s metabolic blockbusters Mounjaro and Zepbound that have vitamin B12 added to them may be unsafe, Lilly said Thursday.
Lilly and its fellow GLP-1-based drugmaker Novo Nordisk have …
Switching GLP-1 Medications Is Common, Can Help People Stick With Weight-Loss Treatment
THURSDAY, March 12, 2026 — People frequently switch between different weight-loss drugs, swapping Ozempic for Zepbound and vice versa within the first year of treatment, a new study reports.What’s more, those patients who do swap GLP-1 drugs are mor…
STAT+: The FDA is targeting telehealth marketing of GLP-1 drugs. Who’s prescribing them?
The FDA is targeting telehealth marketing of GLP-1 drugs. But those companies may not be the only ones under the microscope.
Ozempic-maker Novo Nordisk struggles as GLP-1 drugs continue to dominate medicine, culture
The FDA criticized the maker of Ozempic and Wegovy, Novo Nordisk, for “serious violations” related to the reporting of possible side effects linked to semaglutide, the active ingredient in the drug. NBC News’ Emily Lorsch reports on the GLP-1 drugs.
FDA Warns GLP-1 Maker Over Failure to Properly Report Deaths, Strokes
(MedPage Today) — The FDA issued a warning letter to Novo Nordisk for failing to report and investigate potentially serious side effects associated with its popular GLP-1 medications.
In a letter dated March 5 and made public on Tuesday, the…
GLP-1 Drugs May Benefit Cancer Patients With Brain Lesions
(MedPage Today) — GLP-1 receptor agonist use was associated with a lower risk of death in cancer patients with brain metastases and type 2 diabetes, a retrospective cohort study found.
Within 3 years of a first recorded brain metastasis, patients…